--- title: "Pre-market trend | HUA MEDICINE-B (2552.HK) Bullish signals emerging on 5/14, is there an undercurrent in innovative small-cap stocks?" type: "News" locale: "en" url: "https://longbridge.com/en/news/286384307.md" description: "Yesterday, HUA MEDICINE-B triggered a golden cross signal on the daily MACD zero axis in the Hong Kong stock market, with a trading volume of approximately HKD 4.68 million, which is considered a normal high level for this unprofitable biotech stock. The confirmation of the golden cross above the zero axis on the MACD indicates that a medium-term bullish pattern is beginning to take shape, and buying pressure is accumulating in stages. HUA MEDICINE focuses on the research and development of innovative drugs for diabetes, and its stock price has gradually rebounded from a state of extreme sluggishness, with initial signs of a bottom forming. On the news front, the overall biotech sector in the Hong Kong stock market has recently stabilized after a decline. The news that BAO PHARMA has been included in the MSCI Global Small Cap Index has attracted market attention, indicating a renewed recognition of the value of innovative pharmaceutical companies by international capital. The trading activity of the group of Hong Kong 18A biotech companies has recently increased, with some stocks experiencing unusual capital movements. In addition, frequent mergers and acquisitions in the global pharmaceutical industry have heightened market attention to the pipeline value of unprofitable biotech companies, which could serve as a potential catalyst for R&D-focused pharmaceutical companies like HUA MEDICINE. From a technical perspective, HUA MEDICINE-B has limited liquidity, with a low average daily trading volume, so the reference value of technical signals needs to be assessed in conjunction with changes in trading volume. If the trading volume can maintain above HKD 4 million in subsequent trading days and is accompanied by a positive closing price, the reliability of the signal will be enhanced. The overall trend of the biotech sector and the capital flow of similar 18A stocks are important references. The short-term trend is biased towards bullish but should be approached with caution, as technical signals for small-cap, low-liquidity stocks can easily be distorted by large single orders. Attention should be paid to the company's pipeline progress and changes in sector sentiment" datetime: "2026-05-15T01:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286384307.md) - [en](https://longbridge.com/en/news/286384307.md) - [zh-HK](https://longbridge.com/zh-HK/news/286384307.md) --- # Pre-market trend | HUA MEDICINE-B (2552.HK) Bullish signals emerging on 5/14, is there an undercurrent in innovative small-cap stocks? Yesterday, HUA MEDICINE-B triggered a golden cross signal on the daily MACD zero axis in the Hong Kong stock market, with a trading volume of approximately HKD 4.6845 million, which is considered a normal high level for this unprofitable biotech stock. The confirmation of the golden cross above the zero axis on the MACD indicates that a mid-term bullish pattern is beginning to take shape, and the buying power is accumulating in stages. HUA MEDICINE focuses on the research and development of innovative drugs for diabetes, and its stock price has gradually rebounded from a state of extreme sluggishness, with initial signs of a bottom forming. On the news front, the overall biotech sector in the Hong Kong stock market has recently stabilized after a decline. The news that BAO PHARMA has been included in the MSCI Global Small Cap Index has attracted market attention, indicating a renewed recognition of the value of innovative pharmaceutical companies by international capital. The trading activity of the group of 18A biotech companies in the Hong Kong stock market has recently increased, with some stocks experiencing unusual capital movements. In addition, frequent mergers and acquisitions in the global pharmaceutical industry are raising market awareness of the pipeline value of unprofitable biotech companies, which could serve as a potential catalyst for R&D-focused pharmaceutical companies like HUA MEDICINE. From a technical perspective, HUA MEDICINE-B has limited liquidity, and its average daily trading volume is relatively low, so the reference value of technical signals needs to be assessed in conjunction with changes in trading volume. If the trading volume can maintain above HKD 4 million in subsequent trading days and is accompanied by a positive closing price, the reliability of the signal will be enhanced. The overall trend of the biotech sector and the capital flow of similar 18A stocks are important references. The short-term trend is cautiously bullish, but small-cap, low-liquidity stocks' technical signals can easily be distorted by large single orders. Attention should be paid to the company's pipeline progress and changes in sector sentiment. _This article provides only technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances._ ### Related Stocks - [02552.HK](https://longbridge.com/en/quote/02552.HK.md) - [02659.HK](https://longbridge.com/en/quote/02659.HK.md) - [03069.HK](https://longbridge.com/en/quote/03069.HK.md) ## Related News & Research - [Hua Medicine Announces 2025 Annual Results](https://longbridge.com/en/news/280735000.md) - [11:29 ETLydia Field Joins Family Law Group at Rubin Rudman](https://longbridge.com/en/news/286793706.md) - [Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | DTCFF Stock News](https://longbridge.com/en/news/286870222.md) - [ADNOC Distribution, Americana Restaurants partner to enhance dining convenience, roadside retail across region](https://longbridge.com/en/news/286859556.md) - [13:03 ETLifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension Financing](https://longbridge.com/en/news/286801579.md)